The estimated Net Worth of Bruce A Huebner is at least $10.4 Tisíc dollars as of 19 October 2016. Mr. Huebner owns over 20,000 units of Biocept Inc stock worth over $10,438 and over the last 13 years he sold BIOC stock worth over $0. In addition, he makes $0 as Independent Director at Biocept Inc.
Bruce has made over 3 trades of the Biocept Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of BIOC stock worth $22,000 on 19 October 2016.
The largest trade he's ever made was buying 30,932 units of Biocept Inc stock on 15 November 2011 worth over $52,584. On average, Bruce trades about 4,495 units every 129 days since 2011. As of 19 October 2016 he still owns at least 24,000 units of Biocept Inc stock.
You can see the complete history of Mr. Huebner stock trades at the bottom of the page.
Bruce A. Huebner is no longer serves as Independent Director of the Company effective 11/30/2020. Mr. Huebner was a managing director of LynxCom Partners LLC, a healthcare consulting firm, from 2004 through 2016 where his focus was primarily on cancer diagnostics and personalized medicine. In June of 2011, he joined the board of Vermillion, Inc., an ovarian cancer diagnostics company. He assumed the role of Interim Chief Executive Officer and President of Vermillion from November 2012 to March 2013 and then served as Chairman of the Board from March through December 2013. From October 2009 to June 2010, Mr. Huebner served as President and Chief Executive Officer of TrovaGene, Inc., a developer of molecular diagnostics products. From June of 2005 through June of 2008, Mr. Huebner served as President of Osmetech, Inc., a molecular diagnostic microarray products company. From 2002 to 2004, Mr. Huebner was President and Chief Operating Officer of Nanogen, Inc., a publicly held nanotechnology/microarray company. From 1996 to 2002, Mr. Huebner was Executive Vice-President and Chief Operating Officer of Gen-Probe Incorporated, a leader in the development of nucleic acid tests for infectious diseases. Mr. Huebner received his Bachelor of Science degree in Chemistry from the University of Wisconsin-La Crosse and completed a Senior Executive Graduate School program at Columbia University. We selected Mr. Huebner to serve on our board of directors due to his strong background in cancer diagnostics sales, marketing, operations and reimbursement. Mr. Huebner also serves as chair of our compensation committee, as a member of our audit committee and as a member of our science, technology and clinical affairs committee.
Bruce Huebner is 69, he's been the Independent Director of Biocept Inc since 2013. There are 6 older and 12 younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.
Bruce's mailing address filed with the SEC is C/O BIOCEPT, INC., 5810 NANCY RIDGE DRIVE, SAN DIEGO, CA, 92121.
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff a David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Biocept Inc executives and other stock owners filed with the SEC include: